J. Samuelsson

发表

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

J. Palmblad, E. Ejerblad, J. Thiele, 2013, Hematology.

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.

M. Cazzola, B. Zhivotovsky, L. Nilsson, 2005, Blood.

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.

K. Anderson, Å. Borg, B. Johansson, 2007, Blood.

Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations

B. Zhivotovsky, B. Fadeel, E. Hellström-Lindberg, 2005, Clinical Cancer Research.

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, α‐interferon and betamethasone in a patient with multiple myeloma

E. Björck, J. Samuelsson, 1996 .

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

K. Döhner, T. Barbui, A. Dueck, 2014, Blood.

Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group

K. Döhner, M. Griesshammer, T. Barbui, 2016 .

Further studies of the defective stimulus‐response coupling for the oxidative burst in neutrophils in polycythemia vera

J. Samuelsson, A. Berg, 1991, European journal of haematology.

Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real‐world data from the Swedish MPN Registry

P. Johansson, B. Andreasson, J. Samuelsson, 2017, European journal of haematology.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

K. Döhner, M. Griesshammer, T. Barbui, 2017, Leukemia research.

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

K. Döhner, M. Griesshammer, T. Barbui, 2015 .

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.

P. Lambert, P. Dickman, M. Björkholm, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

M. Griesshammer, N. Kröger, T. Barbui, 2014, Leukemia.

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

M. Björkholm, S. Kristinsson, L. Goldin, 2008, Blood.

Elevated plasma lipoprotein (a)—

K. Leblanc, J. Samuelsson, 1996, European journal of haematology.

Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

A. Wåhlin, A. Engström‐Làurent, G. Birgegard, 2007, Medical oncology.

Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia.

J. Lindgren, C. Edenius, J. Samuelsson, 1991, Blood.

Lipoxygenase products in myeloproliferative disorders: increased leukotriene C4 and decreased lipoxin formation in chronic myeloid leukemia.

J. Palmblad, J. Lindgren, C. Edenius, 1991, Advances in prostaglandin, thromboxane, and leukotriene research.

No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera

K. Leblanc, J. Samuelsson, P. Andersson, 1997, European journal of haematology.

Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

J. Astermark, H. Garelius, L. Kjeldsen, 2011, European journal of haematology.

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 1998, Blood.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

M. Griesshammer, T. Barbui, A. Dueck, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

T. Barbui, A. Dueck, R. Mesa, 2011, Blood.

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

T. Barbui, S. Verstovsek, R. Hoffman, 2013, Blood.

Elevated white blood cell synthesis of leukotriene C4 in chronic myelogenous leukaemia but not in polycythaemia vera

J. Palmblad, J. Lindgren, J. Samuelsson, 1990, British journal of haematology.

Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group

S. Scheding, B. Andreasson, J. Samuelsson, 2022, European journal of haematology.

Myeloproliferative neoplasms – a global view

V. Mathews, P. Hokland, Zhijian Xiao, 2022, British journal of haematology.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

A. Dueck, R. Mesa, A. Vannucchi, 2016, Cancer.

Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera.

T. Lindahl, K. Le Blanc, K. Blanc, 1998, Thrombosis research.

1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.

J. Palmblad, K. Le Blanc, J. Samuelsson, 1995, Biochemical pharmacology.

Stimulus‐specific defect in platelet aggregation in polycythemia vera

J. Palmblad, K. Blanc, J. Samuelsson, 1994, European journal of haematology.

The measurement of venous haematocrit in patients with polycythaemia vera

M. Björkholm, G. Birgegard, H. Wadenvik, 1999, Journal of internal medicine.

Impaired activation of phospholipase D in polycythaemia vera-implications for the pathogenesis of the disease?

J. Samuelsson, 1995, Leukemia & lymphoma.

Survival in patients with familial and sporadic myeloproliferative neoplasms.

M. Björkholm, S. Lund, S. Kristinsson, 2015, Blood.

Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden

M. Björkholm, M. Hultcrantz, T. Andersson, 2022, Leukemia.

Response: More on disease anticipation in familial MPN.

M. Björkholm, S. Kristinsson, L. Goldin, 2008 .

Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms

L. Nilsson, P. Johansson, J. Westin, 2018, European journal of haematology.

Newly Diagnosed Patients with Polycythemia Vera and Essential Thrombocythemia Have an Impaired Quality of Life Compared to Age-Matched Control Individuals

J. Samuelsson, Pettersson, Duncombe, 2019 .

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

G. Gahrton, I. Dybedal, O. Linder, 2003, Leukemia.

Randomized Phase II Study and Long-Term Follow-Up of 71 Patients Colony-Stimulating Factor Plus Erythropoietin: Results From a Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 2009 .

Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor.

G. Lärfars, J. Samuelsson, 1999, Leukemia research.

Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study

E. Kimby, I. Dybedal, A. Öst, 1990 .

Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).

E. Kimby, C. Lindemalm, R. Billström, 1990, European journal of haematology.

Therapeutic effects of low‐dose cytosine arabinoside, alpha‐interferon, 1α‐hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes

G. Gahrton, I. Olsson, A. Öst, 1988, European journal of haematology.

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

M. Møller, H. Hasselbalch, M. Andersen, 2009, Hematology.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

O. Linder, H. Pahl, Y. Brandberg, 2006, Cancer.

Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.

H. Pahl, M. Björkholm, G. Birgegard, 2006, Haematologica.

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

S. Scheding, M. Liljeholm, B. Andreasson, 2019, European journal of haematology.

The Emergence of Hodgkin's Disease in a with Long-standing Chronic Lymphocytic Patient Leukemia Case Report and Review of the Literuture

J. Samuelsson, L. Lundberg, 1997 .

The emergence of Hodgkin's disease in a patient with long-standing chronic lymphocytic leukemia--case report and review of the literature.

J. Samuelsson, L. Lundberg, 1997, Acta oncologica.

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

E. Ejerblad, R. Mesa, P. Johansson, 2013, Leukemia & lymphoma.

A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemia

O. Linder, H. Pahl, Y. Brandberg, 2006 .

A Phase II Trial of Pegylated Interferon -2b Therapy for Polycythemia Vera and Essential Thrombocythemia Feasibility, Clinical and Biologic Effects, and Impact on Quality of Life

O. Linder, H. Pahl, Y. Brandberg, 2006 .

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms

M. Björkholm, S. Kristinsson, L. Goldin, 2009, Genome Medicine.

Survival in a patient with polycythaemia vera for over thirty years: implications for treatment decisions in younger patients.

J. Samuelsson, 1998, Leukemia & lymphoma.

Neutrophil function in polycythemia vera.

J. Samuelsson, 1991, Advances in experimental medicine and biology.

Stimulus‐specific defect in oxidative metabolism of polymorphonuclear granulocytes in polycythemia vera

J. Palmblad, J. Samuelsson, P. Lindström, 1988, European journal of haematology.

Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden.

M. Björkholm, S. Kristinsson, L. Goldin, 2007 .

Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.

M. Møller, H. Hasselbalch, M. Andersen, 2008 .

Long-standing resolution of anemia in symptomatic low-grade non-hodgkin’s lymphoma patients treated with recombinant human erythropoietin as sole therapy

J. Samuelsson, 2002, Medical oncology.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

M. Jädersten, J. Boultwood, A. Pellagatti, 2005 .

Defective Neutrophil Oxidative Metabolism in Polycythemia Vera Is Associated with an Impaired Activation of Phospholipase D a

J. Palmblad, J. Samuelsson, 1997, Annals of the New York Academy of Sciences.

Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders

J. Palmblad, J. Forslid, J. Hed, 1994, British journal of haematology.

Autoimmunity and the risk of myeloproliferative neoplasms

M. Björkholm, S. Kristinsson, L. Goldin, 2010, Haematologica.

Patients treated with natural (leukocyte‐derived) interferon (IFN)‐α do not develop IFN antibodies

E. Kimby, A. Österborg, H. Mellstedt, 1991, European journal of haematology.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

K. Döhner, M. Griesshammer, T. Barbui, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response

M. Griesshammer, T. Barbui, A. Dueck, 2013 .

Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study

T. Barbui, A. Dueck, R. Mesa, 2016 .

Targeted therapy and outcome in chronic lymphocytic leukemia

M. Höglund, A. Österborg, J. Lundin, 2014 .

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

B. Sander, M. Jädersten, L. Nilsson, 2007, Proceedings of the National Academy of Sciences.

Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Leukemia Group of Middle Sweden.

J. Palmblad, P. Ljungman, B. Lönnqvist, 1992, Scandinavian journal of infectious diseases.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

E. Ejerblad, O. Linder, H. Vestergaard, 2013, Leukemia research.

Redefining the role of interferon in the treatment of malignant diseases.

A. Eggermont, S. Bracarda, J. Samuelsson, 2010, European journal of cancer.

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

E. Ejerblad, H. Hasselbalch, G. Birgegard, 2019, European journal of haematology.

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.

B. Zhivotovsky, B. Fadeel, R. Tehranchi, 2003, Blood.

F. Granath, O. Linder, L. Nilsson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

K. Döhner, M. Griesshammer, T. Barbui, 2016, Haematologica.

Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients

P. Dickman, M. Björkholm, M. Hultcrantz, 2020, Leukemia.

Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients

P. Dickman, M. Björkholm, S. Kristinsson, 2018, Leukemia.

A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia

E. Ejerblad, O. Linder, H. Vestergaard, 2013, British journal of haematology.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

M. Griesshammer, L. Shih, P. Cony-Makhoul, 2022, Blood advances.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 2003, British journal of haematology.

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, alpha-interferon and betamethasone in a patient with multiple myeloma.

E. Björck, J. Samuelsson, 1996, European journal of haematology.

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

J. Palmblad, M. Björkholm, G. Birgegard, 2004, Haematologica.

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

J. Palmblad, M. Björkholm, G. Birgegard, 2008, International journal of medical sciences.

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

J. Palmblad, M. Björkholm, J. Westin, 2002, Medical oncology.

Outcome and characteristics of non‐measurable myeloma: A cohort study with population‐based data from the Swedish Myeloma Registry

U. Mellqvist, O. Linder, G. Juliusson, 2019, European Journal of Haematology.

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms

R. Mesa, P. Johansson, R. Scherber, 2012, Leukemia & lymphoma.

Spontaneous Patient Remission During Two Pregnancies in a with Essential Thrombocythaemia

J. Samuelsson, 1997 .

Spontaneous remission during two pregnancies in a patient with essential thrombocythaemia.

B. Swolin, J. Samuelsson, 1997, Leukemia & lymphoma.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

M. Griesshammer, P. Guglielmelli, A. Vannucchi, 2016, Haematologica.

A pilot study of piperacillin and ciprofloxacin as initial therapy for fever in severely neutropenic leukemia patients.

J. Palmblad, A. Wåhlin, I. Winqvist, 1992, Scandinavian journal of infectious diseases.

Monocytosis in primary care and risk of haematological malignancies

C. Andersen, V. Siersma, M. Kriegbaum, 2022, European journal of haematology.

Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden

P. Dickman, M. Björkholm, S. Kristinsson, 2020, Journal of internal medicine.

Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS

T. Barbui, A. Dueck, R. Mesa, 2012 .

Interactions between alkylglycerols and human neutrophil granulocytes.

J. Palmblad, J. Samuelsson, J. Brohult, 1990, Scandinavian journal of clinical and laboratory investigation.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life

Ø. Bruserud, O. Linder, H. Pahl, 2006 .

Defective platelet aggregation in polycythaemia vera is not caused by impaired calcium signaling, phospholipase D activation or decreased amounts of focal adhesion proteins

J. Palmblad, K. Le Blanc, J. Samuelsson, 2000, European journal of haematology.

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

E. Ejerblad, O. Linder, H. Vestergaard, 2012 .

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

M. Griesshammer, T. Barbui, A. Dueck, 2016 .

syndromes characterize early erythroid precursors in low-risk myelodysplastic Aberrant mitochondrial iron distribution and maturation arrest

M. Cazzola, B. Zhivotovsky, L. Nilsson, 2013 .

Fludarabine, as well as 2‐chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies

J. Samuelsson, Gerd LA¨rfars, Ann‐Mari Udén‐Blohmé, 1996, British journal of haematology.

Thromboembolism prophylaxis in patients with Philadelphia‐negative myeloproliferative neoplasms—Clinical practice among Nordic specialists

C. Andersen, O. Bjerrum, M. Kauppila, 2018, European journal of haematology.

A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

E. Ejerblad, L. Nilsson, P. Johansson, 2014 .

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients

T. Barbui, A. Dueck, R. Mesa, 2010 .

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Ø. Bruserud, O. Linder, L. Nilsson, 2004 .